Quantum-Si Pushes Proteus Launch to Q2 2027, Cuts 20% of Workforce as It Adds Extra Design Cycle to De-Risk Platform
Q2 2026 earnings call, August 13, 2026
Quantum-Si used its second-quarter earnings call to deliver news that will reset investor expectations for its flagship Proteus protein sequencing platform: the launch has slipped from the end of 2026 to the second quarter of 2027, a delay the company is pairing with a 20% reduction in headcount and a restructuring of program leadership. CEO Jeffrey Hawkins framed the decision as a deliberate trade-off between speed and reliability, telling analysts the company would rather "de-risk the platform before production than to move forward before product readiness is fully demonstrated."
Why the delay: manufacturing repeatability, not technology risk
The company was explicit that the slippage is not a referendum on the underlying science. Hawkins said Quantum-Si has "generated sufficient sequencing data from integrated units that we remain confident in the underlying technology," and reiterated the point twice during prepared remarks. Instead, the issue is repeatability across the fleet of integrated units built so far in 2026. Some instruments are performing above internal specifications, Hawkins explained, while others are performing at or below target, and the additional design cycle is meant to unify that performance profile before scaling into production. The company also flagged design-for-manufacturability improvements to the optical module and its integration with the instrument, an area Hawkins described as "more challenging and sort of longer" than originally expected, given it is built by one partner and integrated by another. Management stressed the change was internally driven rather than a response to customer feedback. "It wasn't driven by some sort of new feedback from customers that caused us to believe we need to add some capabilities we weren't planning for," Hawkins told analyst Scott Henry of Alliance Global Partners. Notably, the delay is confined to hardware. CFO Jeffry Keyes confirmed reagent and consumable development is "very hardware-focused" in terms of what's driving the change, with the Recognizer enzyme and library-prep workstreams tracking to expectations.
Amino acid coverage lands at 19 or 20, up from prior plan of 18
One silver lining from the delay: Quantum-Si now expects to launch Proteus with detection of either 19 or 20 amino acids, an upgrade from the 18-amino-acid kit it had previously targeted for a year-end 2026 launch, with 20 not arriving until sometime in 2027. Hawkins was candid that the practical benefit of moving from 18 to 20 is limited for most use cases, since the additional amino acids captured are lower in natural abundance. "Outside of a small number of applications where you really need all 20, it doesn't really open up a lot of markets," he said, comparing it to the shift from SNP arrays to whole-genome sequencing in DNA: the value is less about unlocking new science and more about removing friction from the sales conversation. "You don't have to justify why 18 isn't enough anymore," as analyst Michael Okunewitch of Maxim Group put it.
New library-prep strategy: from one generic kit to an application-specific suite
Perhaps the most substantive strategic shift disclosed on the call was in library preparation, the process of digesting proteins into peptides and attaching them to the sequencing array. Historically Quantum-Si built a single general-purpose kit meant to work across all protein types. Real-world data from Platinum placements has pushed the company toward a suite of application-specific kits instead. Hawkins argued this reduces both technical risk on the development side and the customer's burden of optimization, saying a single kit trying to perform "optimally across every protein type and workflow" is inherently harder to build than a portfolio of purpose-built kits. This positions the library-prep suite to launch alongside Proteus.
Sizing the non-human proteomics opportunity at over $4 billion
Quantum-Si used Platinum's commercial deployment to quantify a market it hadn't previously sized publicly: non-human proteomics, spanning pathogen detection, agricultural research, and biosecurity applications. Management pegged this opportunity at more than $4 billion annually, based on the pathogen and agricultural research segments alone, explicitly excluding environmental, animal health, industrial, and food applications where the company's understanding is still developing. Hawkins called the figure "conservative." The company pointed to published research from the U.S. Naval Research Laboratory using its sequencing technology for pathogen and toxin detection, plus active engagements with multiple branches of the U.S. military and militaries outside the U.S. The strategic logic: these markets often lack a defined reference sequence to compare against, a structural weakness for competing technologies that plays to Quantum-Si's single-molecule, reference-free approach. On the human side, the company disclosed a specific biopharma use case in Europe applying protein sequencing to AAV serotyping for gene therapy manufacturing, an application where Platinum could detect relevant amino acid differences between viral vector serotypes but lacked the sequencing depth for routine use. Modeling based on Proteus's higher nanowell count suggests the platform will clear that sensitivity bar, and management noted more than 150 biotech and pharma companies currently develop AAV-based gene therapies.
Revenue remains negligible, guidance held despite the reset
The commercial numbers underscore how early-stage this remains: second-quarter revenue was $344,000, down from $591,000 a year earlier, and first-half revenue fell to $602,000 from $1.4 million. Gross margin was 50% in the quarter but only 41% year-to-date. Management attributed the decline to deliberately limited near-term Platinum capital sales as customers await Proteus. Net loss narrowed slightly to $23.5 million from $28.8 million, and adjusted EBITDA improved modestly to negative $21.2 million from negative $22.2 million. Despite the roadmap change, the company reiterated full-year 2026 guidance of approximately $1 million in revenue, adjusted operating expenses of $98 million or less, and total cash usage of $93 million or less.
Cost cuts extend runway to Q4 2028
The reduction in force, cutting roughly 20% of total headcount, is expected to generate approximately $12 million in annualized operating expense savings once fully implemented, with benefits beginning to show in the fourth quarter after severance costs are absorbed. Combined with $169.9 million in cash, equivalents, and marketable securities as of June 30, the company now says it has runway into the fourth quarter of 2028, a meaningful extension that gives Quantum-Si room to absorb further slippage without an imminent capital raise. Keyes noted R&D spending will stay "relatively consistent" with prior quarters even as SG&A absorbs most of the cuts, since program-critical spending is being protected.
Early access and customer sample testing pushed into 2027
The knock-on effect of the hardware delay is that Quantum-Si's early access program, which had not yet formally started, will now likely begin in early 2027 rather than before year-end 2026. Management indicated it hopes to open a customer sample evaluation program in advance of that, potentially around the end of 2026 or beginning of 2027, but gave no firm date. In the interim, the company said it retains sufficient Platinum Pro inventory to keep prospective customers engaged through its existing placement program, which allows labs to trial the older-generation instrument without a capital purchase.
Semiconductor exposure diminishes with the shift from Platinum to Proteus
One structural positive buried in the Q&A: Quantum-Si's consumable exposure to semiconductor foundry capacity and pricing, a persistent risk with Platinum's CMOS-chip-based consumables, essentially disappears with Proteus, whose consumable is a fused silica glass array rather than a chip. Hawkins said the company remains a "small player" in GPU consumption for onboard data analysis and plans to stockpile ahead of production given long lead times industry-wide, but does not view chip inflation as a meaningful constraint on the Proteus ramp.